This Multibagger Pharma Stock Rallies 5% as It Signs a Strategic Europe-Focused Biosimilar Partnership; Targets USD 4.1 Billion Market

On Tuesday, Indian benchmark indices traded nearly flat, with the Nifty 50 slipping 2.75 points to 23,943.50. Amid the subdued market sentiment, Shilpa Medicare  jumped4.52 per cent to Rs 599.50 after the company announced a strategic biologics partnership with Orion Corporation, Finland, to co-develop and supply an intravenous nivolumab biosimilar for Europe.

Partnership Targets USD 4.1 Billion Immuno-Oncology Market

Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare, has entered into a co-development and supply agreement with Orion Corporation, a globally recognised pharmaceutical company headquartered in Finland, for an intravenous (IV) nivolumab biosimilar, one of the world's most widely used cancer immunotherapies. The collaboration targets the European market, where the originator product is approaching loss of exclusivity, creating a significant opportunity for biosimilars.

According to IQVIA/IMS data cited by the company, nivolumab generated approximately USD 4.1 billion in European sales during 2025, highlighting the sizeable commercial opportunity. The partnership aims to expand patient access to high-quality biosimilars while helping healthcare systems manage rising oncology treatment costs.

Roles of Both Companies

Under the agreement, Orion Corporation will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe and will act as the Marketing Authorisation holder in the region.

Meanwhile, Shilpa Biologicals will lead product development and serve as the exclusive long-term commercial manufacturer and supplier from its advanced EU-GMP-certified biologics facility in Dharwad, India. Besides long-term supply revenue, Shilpa will also receive certain development and regulatory milestone payments from Orion, while the financial consideration remains confidential.

Management Commentary

Commenting on the partnership, Vishnukant Bhutada, Managing Director, Shilpa Medicare, said: "Extending our partnership with Orion into immuno-oncology is a defining moment for Shilpa Biologicals. It reflects the trust our partners place in our quality, our science and our ability to deliver complex biologics at scale  and it moves us closer to our mission of making advanced medicines affordable and accessible worldwide."

Satu Ahomäki, EVP Generics and Consumer Health, Orion Pharma, added: "We are pleased to add yet another product to our strategic partnership with Shilpa. This agreement is a step forward in our efforts to expand and strengthen our operations in hospital segment in Continental Europe, and an indication of the progress of the implementation of our division's strategy which aims to create everybody an access to affordable quality medicines."
Also Read - 5.9 GW Order Book: Stock Below Rs 60 Secures 105 MW Order for Newly Launched 5 MW Wind Turbine

Building on an Existing Partnership

This agreement expands the long-standing relationship between the two companies following their earlier collaboration to commercialise Recombinant Human Albumin in Europe. By combining Shilpa's integrated biologics development and manufacturing capabilities with Orion's commercial reach, regulatory expertise and established distribution network, the partners aim to strengthen access to advanced immuno-oncology therapies across Europe.

About Shilpa Medicare

Shilpa Medicare Limited is a diversified pharmaceutical and biotechnology company engaged in the development and manufacturing of complex generics, biologics and active pharmaceutical ingredients (APIs). Through its wholly owned subsidiary, Shilpa Biologicals, the company operates a fully integrated biologics platform spanning development, scale-up and commercial manufacturing from its EU-GMP-certified biologics facility in Dharwad, India, with a strong focus on innovation, quality and affordability in global healthcare.

What are your thoughts on Shilpa Medicare's latest European biosimilar partnership? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.